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Ha-ras restriction fragment length polymorphisms in colorectal cancer
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Summary The possibility of an association between restriction fragment length polymorphisms (RFLPs) at
the Ha-ras gene locus and susceptibility to develop colorectal cancer has been investigated. Leucocyte DNA
from 46 carcinoma patients and 49 controls was analysed by Southern blotting to determine the size
distribution of restriction fragments containing the variable tandem repeat 3' to the Ha-ras gene. Four
predominant allelic fragments were found in both groups (in AvalI digests having sizes of 1.55, 2.0, 2.65 and
3.15 kilobases [kb]), together with a variety of 'rare' alleles (with individual frequencies <5%). The overall
prevalence of rare alleles was not significantly different between cancer and control groups. The distribution
of the common alleles, however, differed significantly. The combined frequency of the two larger alleles (a3
and a4) was approximately twice as high in the cancer group (34%) as in controls (18%) (P<0.025), which
was reflected in a highly significant increase in the proportion of individuals carrying an a3 or a4 allele.
Activation of the ras family of oncogenes (Ha-, Ki- or N-
ras) has been demonstrated in around 10-20% of randomly-
selected human tumours (Balmain, 1985; Marshall, 1986). In
most cases the mechanism of activation appears to be a
somatic point mutation at one of a few critical sites (codons
12, 13 or 61) and two recent studies have revealed a
particularly high incidence (up to 40%) of such a mutation
in human colonic cancer DNA (Bos et al., 1987; Forrester et
al., 1987). Oncogene activation can, however, result not from
changes in the coding region but from inappropriate
expression of an otherwise normal gene product, as in the
case of c-myc in B cell lymphomas (Leder et al., 1983). There
is increasing evidence that such quantitative changes may
also be involved in ras activation. Experimentally, elevation
of expression can be sufficient to permit a normal Ha-ras
gene to transform NIH3T3 cells (Chang et al., 1982) and to
immortalise primary fibroblasts (Spandidos & Wilkie, 1984).
Direct observations on human material have revealed
apparent increases in ras mRNA or p21 protein content in
tumour versus normal cells in colon (Thor et al., 1984;
Spandidos & Kerr, 1984; Gallick et al., 1985), as well as
breast (Ohuchi et al., 1986) and lung cancers (Kurzrock et
al., 1986). In contrast to c-myc, however, no structural
changes in regulatory sequences have been identified in
tumour ras genes which could account for an increase in
expression as a somatic event.
In addition to somatic changes in oncogene structure,
confined to tumour cells, however, the possibility must also
be considered that constitutional differences in oncogene
structure and/or expression could influence the likelihood of
malignant transformation, by determining, for example, the
number of additional somatic events required for tumouri-
genesis in any given tissue. Southern blot analysis of
germline human Ha-ras genes (Goldfarb et al., 1982) shows
frequent restriction fragment length polymorphisms due to
variation in the copy-number of a tandemly-repeated 28bp
sequence located
- 1 kb downstream from the gene (Capon
et al., 1983). This variable tandem repeat (VTR) has been
proposed as a possible candidate for a flanking sequence
which might influence ras gene expression (Figure 1).
Krontiris et al. (1985) in a large survey of Ha-ras RFLPs
in leucocyte (germ-line) DNA from patients with a variety of
cancers together with unaffected controls found that whereas
in both groups the majority (>85%) of allelic restriction
fragments fell into just four 'common' sizes, in the cancer
population there was a significantly higher prevalence
(11.6% vs. 3.9%) of 'rare' fragment sizes, some of which
Correspondence: D. Wynford-Thomas.
Received 6 August 1987; and in revised form, 8 October 1987.
B B Fln fI fl V77n/A
A A
Figure 1 Schematic representation of the human c-Ha-ras gene
locus. Exons are represented by open boxes and the variable
tandem repeat region by the hatched box. Recognition sites for
restriction endonucleases are shown for BamHl (B) and Avall
(A).
were never observed in the control group. It was suggested
that the existence of these rare alleles might reflect an
inherited abnormality, either specific to the Ha-ras locus or
perhaps representing a more general genomic instability,
which predisposed to the development of cancer.
Since the risk of malignancy may be cell-type specific the
observed effect in this and a later series of mixed cancers
(Krontiris et al., 1986) may have been seriously 'diluted'. We
and others (Thein et al., 1986; Heighway et al., 1986;
Gerhard et al., 1987) have therefore carried out a similar
analysis of patients with a single tumour category. We chose
to investigate colorectal cancer since it is one of the
commonest in Western countries and has a particularly
strong familial tendency (around a quarter of patients have a
first-degree relative with the same disease- Lovett, 1976).
Materials and methods
Subjects
Forty-six patients who had undergone surgery for
histologically-confirmed carcinoma of the colon or rectum
were studied, together with 49 healthy controls with no
family history of cancer in first-degree relatives.
Tumours
Eighteen tumours were situated in the rectum, 14 in the
sigmoid colon, 6 in the caecum, 3 in the descending and 3 in
the ascending colon. The majority (40) were standard adeno-
carcinomas; 6 were classified as mucinous. Two were well-,
33 were moderately- and 11 were poorly-differentiated as
defined by standard histopathological criteria (Dukes, 1949).
Four were at Dukes' stage A, 20 at stage B and 19 at stage
C (2 were examined by biopsy only and 1 was inoperable).
DNA extraction
DNA was prepared from peripheral blood leucocytes by the
method of Kunkel et al. (1977) modified by the addition of
sodium perchlorate (to 1 M) after the proteinase K digestion
step.
C) The Macmillan Press Ltd., 1988 Br. J. Cancer (1988), 57, 135-138136 F.S. WYLLIE et al.
Probe
The plasmid used was pbcN-1 (Pulciani et al., 1982) which
contains a 6.6kb human genomic BamHI fragment including
the c-Ha-ras 1 gene and 3' VTR region.
Southern blot analysis
Genomic DNA (5-10ug per lane) was digested with
restriction endonuclease BamH1 or AvaIl, fractionated on
0.6% or 1.0% agarose gels respectively and blotted to nylon
membranes (Hybond, Amersham, UK). The 6.6kb insert
of pbc-Nl was 32P-labelled to a specific activity of
109cpm g-1 using the random primer method (Feinberg
& Vogelstein, 1983). Hybridisation and washing were carried
out as recommended by the manufacturers to a final
stringency of 0.1 x SSC at 65°C. Membranes were autoradio-
graphed at -70°C for 1-3 days. Fragment sizes were
determined from the migration of co-electrophoresed HindlIl
restriction fragments of bacteriophage A.
Statistical analysis
The significance of differences in allele frequency were
assessed by the chi-square test, corrected for continuity
where appropriate (Armitage, 1971).
Results
Initial analysis with BamHl (Figure 2A) showed 4 common
restriction fragment sizes of 6.6, 7.0, 7.6 and 8.0kb,
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representing alleles designated al, a2, a3 and a4. However,
the large size of these fragments relative to the VTR
seriously limited resolution so that alleles varying in size by
<0.2kb could not be reliably distinguished. Accordingly, the
major study of allele size distributions was based on samples
digested with Avall, which cuts just outside the VTR,
generating fragments for alleles al to a4 of 1.55, 2.0, 2.65
and 3.15kb respectively. The resulting improvement in
resolution is evident from comparison of Figures 2A and 2B.
All samples were nevertheless also analysed by BamH1
digestion to ensure that variations in allele size observed in
Avall digests were indeed due to variations in the length of
the VTR and not to a restriction site polymorphism for
Avall, which is occasionally found (Thein et al., 1986).
Several sources of variability which could affect the
precision of Avall fragment size measurement were
considered. Inter-gel variation was overcome by including
samples representing the known common alleles (al to a4) in
each gel to act as an internal standard (in addition to the
HindlIl markers). Within a given gel, significant variation in
apparent fragment size was observed to result in early
studies from variation in DNA loading; an apparent
decrease of as much as 0.1 kb could result from a 3-fold
increase in loading. Care was taken therefore to load equal
O.D.260 units of sample on each lane and to further check
for equality of loading by inspection of the ethidium
bromide-stained gel prior to blotting.
With these precautions, comparison of samples from
different patients having the same genotype run on the same
gel gave a mean and standard deviation (s.d.) of fragment
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Figure 2 Comparison of the 4 'common' Ha-ras alleles in leucocyte DNA digested with BamHl (A) or Avall (B) and
fractionated on 0.6% (A) or 1% (B) agarose gels respectively. The alleles shown are: lane a: a3, a2, al (composite of two samples
used as internal standard); lane b: a4, al; lane c: al, al; lane d: a3, al. (M: size markers in kb.)Ha-ras RFLPs IN COLORECTAL CANCER 137
size for alleles al, a2, a3 and a4 of 1.55+0.02kb,
2.0 +0.04kb, 2.65+0.06kb and 3.15 +0.10kb respectively.
These correspond to 95% confidence intervals (2 xs.d.) for
determination of these allele sizes, of 0.04kb, 0.08kb, 0.12kb
and 0.2kb respectively. We were able, for example, to
reproducibly distinguish between alleles in the 1.5-2.0kb
range which differed by only 100bp (e.g., aS vs. a6 in Figure
3). A 'rare' allele was defined as having a fragment size >2
s.d. from the nearest 'common' allele (al, a2, a3 or a4).
On this basis five rare alleles with sizes from 1.6kb to
2.8 kb were detected (Table I; Figure 3). The overall
frequency of rare alleles was 2.0% (2/98) in the control
population compared with 7.6% (7/92) in the cancer
patients. This difference was not statistically significant
(X2 =2.1; P>0.1). However, comparison of the frequencies
of all alleles between cancer and normal groups revealed a
significant overall difference (x2= 10.5; P<0.05). Further
analysis showed that the two largest common alleles, a3 and
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Figure 3 Common and rare Ha-ras alleles in control and cancer
patients. Leucocyte DNA from control (lane a) and from
colorectal cancer patients (lanes b to g) were digested with Avall
and fractionated on an 0.6% gel. The represented genotypes are
- lane a: a4, al; lane b: a8, al; lane c: a4, al; lane d: a4, a5;
lane e: a4, a3, al*; lane f: a3, al; lane g: a3, a6. Rare alleles
(aS, a6 and a8) are arrowed. (M: size markers in kb.)
*This is an internal standard composed of 2 samples (a4/al
and a3/al).
Table I Comparison of Ha-ras allele frequencies in
patients with colorectal cancer and in an unaffected
population
Frequencya
Size Cancer Unaffected
Allele (kb) patients controls
Fal 1.55 48 (53) 68 (69)
Common a2 2.0 6 (6.5) 10 (10) Common 1 a3 2.65 18 (20) 11 (11)
La4 3.15 13 (14) 7 (7.1)
[a5 1.6 1 (1.1)
a6 1.7 4(4.4) 1 (1)
Rare a7 2.2 1 (1.1)
a8 2.78 1 (1.1) -
La9 2.8 - 1 (1)
Total 92 (100) 98 (100)
aFigures in brackets are percentages of the totals.
2.2-
1.9-
a4, were much more frequent in cancer patients, the
combined frequency of a3 plus a4 being almost twice that in
controls (31/92 vs. 18/98; x2=5.05; P<0.025). This was
reflected in a highly significant increase in the proportion of
individuals carrying an a3 or a4 allele in the cancer group
(29 out of 46) compared with the normals (15 out of 49)
(X2=8.8; P<0.01). No other significant difference of either
single or combined allele or genotype frequency was
observed.
Sub-division of the cancer group by differentiation grade
or clinical stage showed no correlation of rare allele
frequency with any sub-type. The combined prevalence of
the a3 and a4 alleles increased with decreasing differentiation
but this failed to reach statistical significance (Table II).
Discussion
Our analysis of Ha-ras RFLPs in patients with a single
tumour type - colorectal carcinoma - shows that in contrast
to the results of a larger survey of mixed tumour categories
(Krontiris et al., 1985) the frequency of rare alleles was not
significantly increased in germline (leucocyte) DNA from the
cancer group compared with a control population. Krontiris'
studies showed a similar incidence in controls to our own,
i.e., 3.9% (Krontiris et al., 1985) and 3.4% (Krontiris et al.,
1986), but a highly significant increase (P<0.01 and
P<0.001 respectively) in the cancer patients, which was not
diminished when the solid tumour sub group was considered
separately. (The majority of cases were leukaemias.) While
our study was proceeding other similar analyses of specific
tumours were reported. Thein et al. (1986) found rare alleles
at a frequency of 2.8% in patients with myelodysplastic
syndrome (MDS) compared with 4.8% in their controls.
Gerhard et al. (1987) reported a rare allele prevalence of 4%
in melanoma against 6% in controls, an interesting contrast
to the 43% (6/14) seen in the Krontiris series. Similarly
Heighway et al. (1986) reported figures of 5 to 7% in lung
cancers compared with 4% in controls. All three therefore
agree with our failure to demonstrate any significant over-
representation of rare alleles in tumour patients. One striking
exception is the report by Liderau et al. (1986) of an
apparent increase in rare allele frequency from 9% in
controls to 41% in breast cancer patients.
Although more surveys will be needed before any final
conclusion can be reached, it is already clear therefore that
the association of rare Ha-ras alleles with cancer
predisposition does not hold for most tumour types so far
examined. It should be pointed out, however, that the
importance of considering all sources of artefact affecting the
migration and hence apparent size of fragments in these
Southern blot analyses has not been sufficiently stressed. We
observed in preliminary studies, for example, that leucocyte
and tumour DNA samples obtained from the same patients,
Table II Combined frequencies of a3 plus a4 alleles in
unaffected controls and in patients with colorectal cancer
of different grade and stage
Frequencya
Unaffected controls 18/98 (18)
Cancer patients:
-Poorly differentiated 9/22 (41)
Grade - Moderately differentiated 21/66 (32)
LWell differentiated 1/4 (25)
fDukes' A 5/8 (63)
Stage - Dukes' B 14/40 (35)
LDukes' C 12/38 (32)
All cancer patients 31/92 (34)
aFrequency of a3 plus a4 as proportion of total alleles
in each group; Figures in brackets are percentages.138 F.S. WYLLIE et al.
but extracted (for other reasons) by different methods,
frequently showed a. - slight difference in migration
corresponding to an apparent size difference of up to a few
hundred base pairs. This could be particularly important
where comparison is based on leucocyte DNA for controls
but tumour DNA for cancer patients (e.g., Liderau et al.,
1986). The finding of an apparent rare/rare genotype, in
which a similar deviation from normal is observed in both
alleles, could well be due to such an artefact.
Although no change in the incidence of rare alleles was
seen in our study, a significant change in the relative
abundance of the four normal alleles was observed,
consisting of an increase in the rarer a3 and a4 alleles with a
corresponding fall in the frequency of al and a2. In contrast
to the increased a3 plus a4 frequency from 18 to 34% seen
here in colorectal cancer patients, no increases were reported
in the mixed tumour series (or solid tumour subgroup) of
Krontiris et al. (1985) or in the MDS, melanoma and breast
studies referred to above. Our result agrees closely however
with the observation of a similar magnitude increase (15-
29%) in the incidence of the a4 allele in one sub-type of lung
cancer - non-small cell carcinoma (Heighway et al., 1986).
There are at least two possible explanations for this
finding. First it may represent an indirect association in
which the longer, a3 or a4, alleles are in linkage disequi-
librium with a cancer-predisposing allele of a neighbouring
locus. Alternatively, it may represent a true direct association
in which the increased length of VTR in some way
contributes to an increased risk of developing cancer. It has
been suggested that the VTR region may have an enhancer-
like activity since its removal leads to a decrease in trans-
forming efficiency of mutant Ha-ras gene clones (Krontiris et
al., 1985) and to a decreased expression of the normal gene
(Seeburg et al., 1984). It is possible therefore that gene
expression is increased by a lengthening of the VTR. It is
unlikely, however, that any of the RFLPs at the Ha-ras
locus play a direct role in generating the tumour phenotype;
none of the common or rare Ha-ras alleles shows trans-
forming activity in the NIH3T3 assay for example (Krontiris
et al., 1985). More likely, possession of a given allele
modulates the action of the primary oncogene abnormalities
(for example Ki-ras mutation) thereby acting as one of a
multiple set of hereditary factors which combine to influence
the risk of tumour development.
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